Soquelitinib - CAS 2226636-04-8

Soquelitinib (CPI-818) is a covalent, irreversible, oral and selective ITK inhibitor that preferentially inhibits Th2 cytokine production over Th1, inhibits in vivo tumor growth in mice, and decreases markers of T-cell exhaustion, resulting in an increase in tumor infiltration and up-regulation of CXCR3, IFNγ, TNFα, and CD107a expression in normal CD8 cells.

COX, Immunology/Inflammation related, IL Receptor, CXCR, Tyrosine Kinases, TNF

Neuroscience, Apoptosis, Tyrosine Kinase/Adaptors, GPCR/G Protein, Immunology/Inflammation, Autophagy

2226636-04-8

0.9954

C25H30N4O4S2

514.66

C(=O)(C1=C(OC)C=C(C)C(SC=2SC(NC(=O)C3CC3)=NC2)=C1)N4C[C@@H](C)N(C(C=C)=O)CCC4

-20°C

Ice Packs

Small Compound